Display options
Cite
Bergeron E, Bensoussan M. Massively distended, necrotic and hemorrhagic gallbladder in a long-term octreotide-treated patient with added everolimus. Int J Surg Case Rep. 2019;61:107-110doi: 10.1016/j.ijscr.2019.07.014.
Bergeron, E., & Bensoussan, M. (2019). Massively distended, necrotic and hemorrhagic gallbladder in a long-term octreotide-treated patient with added everolimus. International journal of surgery case reports, 61107-110. https://doi.org/10.1016/j.ijscr.2019.07.014
Bergeron, Eric, and Bensoussan, Michael. "Massively distended, necrotic and hemorrhagic gallbladder in a long-term octreotide-treated patient with added everolimus." International journal of surgery case reports vol. 61 (2019): 107-110. doi: https://doi.org/10.1016/j.ijscr.2019.07.014
Bergeron E, Bensoussan M. Massively distended, necrotic and hemorrhagic gallbladder in a long-term octreotide-treated patient with added everolimus. Int J Surg Case Rep. 2019;61:107-110. doi: 10.1016/j.ijscr.2019.07.014. Epub 2019 Jul 19. PMID: 31352317; PMCID: PMC6664011.
Copy Download .nbib Format: NLM
Share it on

Int J Surg Case Rep. 2019;61:107-110. doi: 10.1016/j.ijscr.2019.07.014. Epub 2019 Jul 19.

Massively distended, necrotic and hemorrhagic gallbladder in a long-term octreotide-treated patient with added everolimus.

International journal of surgery case reports

Eric Bergeron, Michael Bensoussan

Affiliations

  1. Departments of Surgery and Gastroenterology, Charles-LeMoyne Hospital, Greenfield Park, Canada. Electronic address: [email protected].
  2. Departments of Surgery and Gastroenterology, Charles-LeMoyne Hospital, Greenfield Park, Canada.

PMID: 31352317 PMCID: PMC6664011 DOI: 10.1016/j.ijscr.2019.07.014

Abstract

INTRODUCTION: Long-term treatment with somatostatin analogs, such as octreotide, is well known to promote gallstones formation. Immunosuppressive therapy in renal transplantation is also associated with increased occurrence of gallstones. But acute cholecystitis develops only in a few cholelithiasis patients. However, it is not known whether long-term somatostatin analog therapy and immunosuppressants aggravate the severity of disease if the patient develops cholecystitis.

CASE PRESENTATION: We present a case of severe cholecystitis in a patient with metastatic carcinoid cancer on octreotide long-acting release therapy for seven years with newly added immunosuppressant, everolimus.

DISCUSSION: Cholelithiasis as well as cholecystitis develop more often in patients on somatostatin analogs and immunosuppressants than in general population. However, morbidity remains negligible.

CONCLUSION: No conclusion can be drawn on the contribution of somatostatin analogs and immunosuppressant in the occurrence of severe cholecystitis. Prophylactic cholecystectomy is not indicated in patients with this medication.

Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Keywords: Carcinoid cancer; Cholecystitis; Cholelithiasis; Everolimus; Octreotide

References

  1. Best Pract Res Clin Gastroenterol. 2006;20(6):981-96 - PubMed
  2. BMJ. 2007 Aug 11;335(7614):295-9 - PubMed
  3. J Endocrinol Invest. 2008 Aug;31(8):704-10 - PubMed
  4. J Clin Oncol. 2009 Oct 1;27(28):4656-63 - PubMed
  5. World J Surg. 2010 Jun;34(6):1361-7 - PubMed
  6. J Oncol Pharm Pract. 2011 Sep;17(3):274-8 - PubMed
  7. Ann Surg Oncol. 2014 Jan;21(1):240-7 - PubMed
  8. N Engl J Med. 2014 Jul 17;371(3):224-33 - PubMed
  9. Expert Opin Drug Saf. 2015 Aug;14(8):1213-26 - PubMed
  10. J Hepatol. 2016 Jul;65(1):146-181 - PubMed
  11. Ther Clin Risk Manag. 2017 Oct 13;13:1391-1398 - PubMed
  12. Dig Liver Dis. 2019 May;51(5):689-694 - PubMed
  13. Int J Surg. 2018 Dec;60:132-136 - PubMed
  14. Hepatology. 1995 Mar;21(3):655-60 - PubMed
  15. Clin Endocrinol (Oxf). 1994 Mar;40(3):401-6 - PubMed
  16. Cancer. 1997 Feb 15;79(4):830-4 - PubMed

Publication Types